Serum 25-hydroxyvitamin D levels in patients with vulvar cancer

Anticancer Research

Volumn 32, Issue 1 PART 2, 2012, Pages 265-270

  Salehin, Darius ^a   Haugk, Christina ^a   Thill, Marc ^b   Cordes, Tim ^b   Hornung, Daniela ^b   Abu Hechle, Andre ^a   Hemmerlein, Bernhard ^a   Friedrich, Michael ^a  

^a Helios Hospital Krefeld   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

25 Hydroxyvitamin D; Vitamin D; Vulvar cancer

Indexed keywords

25 HYDROXYVITAMIN D;

ADULT; AGED; BLOOD SAMPLING; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; SEASONAL VARIATION; STATISTICAL SIGNIFICANCE; TREND STUDY; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VULVA CANCER;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; RISK FACTORS; SEASONS; SURVIVAL RATE; VITAMIN D; VULVAR NEOPLASMS;

EID: 84856020730     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. Krebs in Deutschland: Häufigkeiten und Trends. Arbeitsgemeinschaft Bevökerungsbezogener Krebsregister in Deutschland, in Zusammenarbeit mit dem Robert-Koch-Institut, 4. überarbeitete, aktualisierte Ausgabe. Saarbrücken, 2004
2. Reinthaller A and Leodolter S: Chirurgische Onkologie. Vulvakarzinom Part 2: 441-447, 2008.
3. Schnürch HG and Meerpohl HG: Kompendium internistische Onkologie. Vulvakarzinom 8: 4765-4788, 2006.
4. Toki T, Kurman RJ, Park JS, Kessis T, Daniel RW and Shah KV: Probable nonpapillomavirus etiology of suamous cell carcinoma of the vulva in older women: a clinicopathologic study using in situ hybridization and polymerase chain reaction. Int J Gynecol Pathol 10: 107-125, 1991.
5. Wilkinson EJ and Teixera MR: Epithelial tumours, squamous tumours: In: World Health Organization Classification of Tumours: Pathology and Genetics: Tumours of the Breast and Female Genital Organs. Tavassoli M, Devilee P (Eds.) Lyon: IARC Press, pp. 230-320, 2003.
6. Landis S, Murray T, Bolden S and Wingo PA: Cancer Statistics. CA Cancer J Clin 48: 6-29, 1998.
7. Sturgeon SR, Briton LA, Devesa SS and Kurman RJ: In situ and invasive vulvar cancer incidence trends (1973 to 1987). Am J Obstet Gynecol 166: 1482-1485, 1992.
8. Giovanucci E: The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 16: 83-95, 2005.
9. Haddad JG and Hahn TJ: Natural and synthetic sources of circulating 25-hydroxyvit-D in man. Nature 244: 515-517, 1973.
10. Slovik DM, Adams JS, Neer RM, Holick MF and Potts JT: Deficient production of 1,25-dihydroxyvitamin D in eldery osteoporotic patients. N Engl J Med 305(7): 372-374, 1981. (Pubitemid 11063752)
11. Holick MF: Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 80: 1678-1688S, 2004.
12. Kimlin MG: Understanding vitamin D ultraviolet radiation. Proceedings of the 13th vitamin D workshop. Victoria, BC, Canada, 2006.
13. Hollis BW and Wagner CL: Normal serum vitamin D levels. N Engl J Med 352(5): 515-516, 2005.
14. Reichrath J: Vitamin D and the skin: an ancient friend, revisted. Experimental Dermatology 16(7): 618-625, 2007.
15. 3. The vitamin D hormone. Internist 40(4): 414-430, 1999.
16. Holick MF: Vitamin D deficiency. N Engl J Med 357: 266-281, 2007.
17. Ebert R, Schütze N, Adamski J and Jakob F: Vitamin D signaling is modulated on multiple levels in health and disease. Mol Cell Endocrinol 248(1-2): 149-59, 2006.
18. Barreto AM, Schwartz GG, Woodruff R and Cramer SD: 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev 9: 265-270, 2000. (Pubitemid 30165438)
19. Ogunkolade WB, Boucher BJ, Fairclough PD, Hitman GA, Dorudi S, Jenkins PJ and Bustin SA: Expression of 25-hydroxyvitamin D-1-α-hydroxylase mRNA in individuals with colorectal cancer. Lancet 359: 1831-1832, 2002. (Pubitemid 34607061)
20. Tangpricha V, Flanagan JN, Whitlach LW, Tseng C, Chen TC, Holt PR, Lipkin MS and Holick MF: 25-Hydroxyvitamin D-1α-hydroxylase in normal and malignant colon tissue. Lancet 357: 1673-1674, 2001. (Pubitemid 32568244)
21. Hewison M, Kantorovich V, Liker HR, van Herle AJ, Cohan P, Zehnder D and Adams JS: Vitamin D-mediated hypercalcemia in lymphoma: evidence of hormone production by tumoradjacent macrophages. J Bone Miner Res 18: 579-582, 2003. (Pubitemid 36241076)
22. Hewison M, Zehnder D, Chakraverty R and Adams JS: Vitamin D and barrier function: a novel role for extra renal 1α-hydroxylase. Mol Cell Endocrinol 215: 31-38, 2004. (Pubitemid 38333240)
23. 3-1alpha-hydroxylase in normal and malignant breast tissue. Anticancer Res 26(4A): 2615-2620, 2006.
24. Cordes T, Fischer D, Thill M, Becker S, Friedrich M and Salehin D: Vitamin D-1alpha-hydroxylase and vitamin D-24-Hydroxylase in benign and malign breast tissue. Eur J Gynaecol Oncol 31(2): 151-155, 2010.
25. Fischer D, Becker S, Cordes T, Bücker B, Diederich K, Friedrich M, Salehin D and Thill M: Vitamin D-24-hydroxylase in benign and malignant breast tissue and cell lines. Anticancer Res 29(9): 3641-3645, 2009.
26. Ogunkolade WB, Boucher BJ, Bustin SA, Burrin JM, Noonan K, Mannan N and Hitman GA: Vitamin D metabolism in peripheral blood mononuclear cells is influenced by chewing "betel nut" (Areca catechu) and Vitamin D status. J Clin Endocrinol Metab 97(7): 2612-2617, 2006. (Pubitemid 44024626)
27. Garland CF, Garland FC, Shaw EK, Comstock GW, Helsing KJ and Gorham ED: Plasma 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 2(8673): 1176-1178, 1989. (Pubitemid 19275448)
28. Schwartz GG and Hulka BS: Is vitamin D deficiency a risk factor for prostate cancer? Anticancer Res 10(5A): 1307-1311, 1990.
29. Eisman JA, Martin TJ and MacIntyre I: 1,25-dihydroxyvitamin D3 receptors in cancer. Lancet 31(1): 1188, 1980.
30. Hansen CM, Hansen D, Holm PK and Binderup L: Vitamin D compounds exert anti-apoptotic effects in human osteosarcoma cells in vitro. J Steroid Biochem Mol Biol 77(1): 1-11, 2001. (Pubitemid 32455348)
31. 3 modulation of mammary tumor cell growth in vitro and in vivo. Breast Cancer Res Treat 27(1-2): 69-81, 1993.
32. Trump DL, Hershberger PA, Bernhardi RJ, Ahmed S, Muindi J, Fakih M, Yu WD and Johnson CS: Anti-tumor activity of Calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol 89-90(1-5): 519-526, 2004.
33. Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG and Colston KW: Plasma 25-hydroxy vitamin D concentrations, vitamin D genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer 41(8): 1164-1169, 2005. (Pubitemid 40725575)
34. Rossi M, McLaughlin JK, Lagiou P, Bosetti C, Talamini R, Lipworth L, Giacosa A, Montella M, Franceschi S, Negri E and La Vecchia C: Vitamin D intake an breast cancer risk: a case-control study in Italy. Ann Oncol 20(2): 374-378, 2009.
35. Zitterman A: Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 89: 552-572, 2003.
36. Dusso AS, Brown AJ and Slatopolsky E: Vitamin D. Am J Physiol Renal Physiol 289(7): F8-28, 2005.
37. Nürnberg B, Gräber S, Gärtner B, Geisel J, Pföhler C, Schadendorf D, Tilgen W and Reichrath J: Reduced Serum 25-Hydroxyvitamin D Levels in Stage IV Melanoma Patients. Anticancer Res 29: 3669-3674, 2009.
38. Hintzpeter B, Mensink GBM, Thierfelder W, Müller MJ and Scheidt-Nave C: Vitamin D levels and health correlates among German adults. Eur J Clin Nutr 62(9): 1079-1089, 2008.
39. Cannell JJ and Hollis BW: Use of vitamin D in clinical practice. Altern Med Rev 13: 6-20, 2008. (Pubitemid 351489580)
40. Lanham-New SA, Buttriss JL, Miles LM, Ashwell M, Berry JL, Boucher BJ, Cashman KD, Cooper C, Darling AL, Francis RM, Fraser WD, de Groot CP, Hyppönen E, Kiely M, Lamberg-Allardt C, Macdonald HM, Martineau AR, Masud T, Mavroeidi A, Nowson C, Prentice A, Stone EM, Reddy S, Vieth R and Williams CM: Proceedings of the Rank Forum on Vitamin D. Br J Nutr 105(1): 144-56, 2010.
41. Reinhold U, Schmitz B, Kurbacher C, Nagel W, Schmidt M and Malaisse WJ: Circulating 25-hydroxyvitamin D concentration in German cancer patients. Oncol Rep 20(6): 1539-1543, 2008.
42. Holick MF: Vitamin D: evolutionary, physiological and health perspectives. Curr Drug Targets 12(1): 4-18, 2011.
43. Querings K and Reichrath J: A plea for detection and treatment of vitamin D deficiency in patients under photoprotection, including patients with xeroderma pigmentosum and basal cell nevus syndrome. Cancer Causes Control 15: 219, 2004. (Pubitemid 38445369)
44. 3 in breast cancer. Anticancer Res 30(5): 1673-1679, 2010.
45. Goodwin PJ, Ennis M, Pritchard KI, Koo J and Hood N: Prognostic effects 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 27(23): 3757-3763, 2009.
46. Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Millet WC and Hankinson SE: Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 14: 1991-1997, 2005. (Pubitemid 41161213)
47. Shin MH, Holmes MD, Hankinson SE, Wu K, Colditz GA and Willet WC: Intake of dairy products, calcium, and vitamin d and risk of breast cancer. J Natl Cancer Inst 94(17): 1301-1311, 2002.
48. Ainsleigh HG: Beneficial effects of sun exposure on cancer mortality. Prev Med 22(1): 132-140, 1993.
49. Knight JA, Lesosky M, Barnett H, Raboud JM and Vieth R: Vitamin D and reduced risk of breast cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 16(3): 422-429, 2007. (Pubitemid 46548644)
50. Grant WB: Ecologic studies of solar UV-B radiation and cancer mortality. Recent Results Cancer Res 164: 371-377, 2003.